-$0.06 Earnings Per Share Expected for BIOLINERX Ltd/S (BLRX) This Quarter
Analysts forecast that BIOLINERX Ltd/S (NASDAQ:BLRX) will report earnings of ($0.06) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for BIOLINERX Ltd/S’s earnings. BIOLINERX Ltd/S posted earnings of ($0.07) per share in the same quarter last year, which would suggest a positive year over year growth rate of 14.3%. The business is scheduled to issue its next earnings report on Tuesday, March 5th.
On average, analysts expect that BIOLINERX Ltd/S will report full-year earnings of ($0.22) per share for the current financial year. For the next fiscal year, analysts forecast that the business will report earnings of ($0.25) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that follow BIOLINERX Ltd/S.
BIOLINERX Ltd/S (NASDAQ:BLRX) last posted its earnings results on Thursday, November 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06).
Shares of NASDAQ:BLRX traded down $0.03 during trading on Wednesday, hitting $0.64. 5,455 shares of the company were exchanged, compared to its average volume of 849,257. The company has a market cap of $71.35 million, a P/E ratio of -2.37 and a beta of 0.87. BIOLINERX Ltd/S has a 52-week low of $0.63 and a 52-week high of $1.84.
A hedge fund recently bought a new stake in BIOLINERX Ltd/S stock. Fosun International Ltd bought a new stake in BIOLINERX Ltd/S (NASDAQ:BLRX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned about 1.27% of BIOLINERX Ltd/S as of its most recent SEC filing. Institutional investors and hedge funds own 35.81% of the company’s stock.
About BIOLINERX Ltd/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
See Also: Trading Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.